The company primarily trades in general merchandise, including metals and garments, while transitioning its core focus toward real estate development and land plotting projects in Gujarat.
The company lacks a durable competitive advantage, as evidenced by its frequent shifts in business focus from printing to general trading and now real estate. Low average ROCE of 8.7% and a negative cash conversion cycle contradict any narrative of pricing power or structural barriers to entry.
Management has historically pivoted capital between unrelated industries, including printing, commodity trading, and real estate. While the company maintains a debt-free balance sheet, the lack of consistent EPS growth and the recent focus on speculative land development suggest a lack of disciplined reinvestment strategy.
The company's history of shifting from printing to commodity trading and finally to speculative real estate culminated in a total loss of focus. Without a core competency, capital was dissipated into land projects that failed to generate liquidity, as evidenced by the already negative cash conversion cycle. The lack of institutional oversight and the absence of internal audit reports eventually masked a terminal decline in asset quality, leaving shareholders with a shell company that produces more 'Other Income' than actual operating cash flow.
RichFakir rates Vivid Mercantile Ltd's business quality as poor — 35/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Vivid Mercantile Ltd is trading about 33% below our estimate of fair value; we rate its price cheap. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Vivid Mercantile Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Vivid Mercantile Ltd's fair value is about ₹9 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →